The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. (Q43791910)

26 November 2017

The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. (English)

1 reference

26 November 2017

0 references

0 references

0 references

N A Darmani

1

1 reference

PubMed ID

11698062

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

European Journal of Pharmacology

26 November 2017

1 reference

26 November 2017

430

1 reference

26 November 2017

49-58

1 reference

26 November 2017

1

1 reference

An efficient new cannabinoid antiemetic in pediatric oncology

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Cannabinoid modulation of intestinal propulsion in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Nabilone: an alternative antiemetic for cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

The 5-HT3 agent N-(3-chlorophenyl)guanidine (MD-354) serves as a discriminative stimulus in rats and displays partial agonist character in a shrew emesis assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Δ9-Tetrahydrocannabinol for Refractory Vomiting Induced by Cancer Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Cannabinoids and appetite stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Pharmacological agents affecting emesis. A review (Part I)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Molecular characterization of a peripheral receptor for cannabinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

The analgesic properties of delta-9-tetrahydrocannabinol and codeine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Antiemetic Effect of Δ9-Tetrahydrocannabinol in Chemotherapy-Associated Nausea and Emesis As Compared to Placebo and Compazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Cannabis and cannabinoids: pharmacology and rationale for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Motor actions of cannabinoids in the basal ganglia output nuclei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Activational role of cannabinoids on movement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Lack of antiemetic effects of delta9-tetrahydrocannabinol in apomorphine-induced emesis in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

The ACTH(4-9) analog Org2766 modulates the behavioral changes induced by NMDA and the NMDA receptor antagonist AP5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Biphasic effects of anandamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Δ9-Tetrahydrocannabinol As An Antiemetic For Patients Receiving Cancer Chemotherapy. A Pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

Clobenzorex: evidence for amphetamine-like behavioral actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901355-3

10.1016/S0014-2999(01)01355-3

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference

PubMed ID

11698062